Michael Tattory

Synaptive Medical announced that its U.S. and Canadian Modus V robotic digital microscope now includes updates such as additional 3D visualization and voice-activated control. The Modus V is a robotically controlled digital microscope used as part of Synaptive’s BrightMatter surgical suite designed for less invasive, patient-specific approaches in complex cranial procedures.

NantKwest Inc. shares rose by a record after the company’s CEO said its experimental cancer therapy had shown a dramatic result in one patient with pancreatic cancer. In an interview with Bloomberg Television, Chief Executive Office Patrick Soon-Shiong said one patient with metastatic pancreatic cancer had their tumors eradicated after treatment with the company’s experimental

Not everyone agrees that MRI is necessary to characterize joint structure. Samumed’s Yazici argued that if a molecule has a meaningful effect size, X-ray should be more than suitable for measuring the benefit. “In RA, if you look at all the approval packages, there’s nothing about MRIs. It is all X-rays because if you have

Valneva’s has made a name for itself by developing vaccines for in-demand illnesses and now the biotech company has its eyes set on Lyme disease. Their Lyme disease vaccine prototype, VLA15 is currently in Phase 2 developments and is being tested on more than 800 people to measure both efficacy and safety. Although difficult to predict,

Nurix Therapeutics Inc. and Sanofi partnered to develop protein degradation therapies for three targets and multiple diseases. Sanofi, which has an option to license compounds for two additional targets, has exclusive rights to the candidates and is responsible for clinical development and commercialization. Nurix, which has a co-development and co-promotion option to up to two

Led by a team of veterans from Alios BioPharma and Janssen, Aligos Therapeutics raised $125 million in a series B round to bring three of its HBV therapies to the clinic this year. Aligos thinks that in combination, the trio of modalities could lead to the development of a functional HBV cure under one roof.

Nurix Therapeutics Inc. landed its second big pharma collaboration in seven months when it signed with Sanofi SA to discover, develop and commercialize a pipeline of protein degradation therapies.

Acepodia’s off-the-shelf cell therapy uses an antibody-cell conjugate to target human HER2-expressing solid tumors.

Startups attempt to revive exhausted T cells to fight solid tumors, but must strike a balance to avoid triggering adverse events.

Gaurav Shah, MD, Chief Executive Officer & President of Rocket Pharmaceuticals explains the advantages that smaller biotech companies have in developing treatments for rare diseases. Rocket Pharmaceuticals is currently developing gene therapies for a number of rare conditions, including Fanconi anemia, Danon disease, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and infantile malignant osteopetrosis.

How do you catch just one kind of fish in a sea of similar fish? That’s the question being answered by researchers at Nurix, except they aren’t catching fish – they are ‘catching’ proteins in your body. Nurix is developing drugs that can specifically target one protein within the hundreds or thousands of extremely similar

It’s no secret that preparation for a colonoscopy is an uncomfortable experience. At times, the preparation can be so off-putting, that some chose to forgo the procedure altogether. For this reason, Check-Cap has created an indigestible capsule for prep-free colon cancer screening to ensure that no patient gets left behind in cancer precaution. The device

Eleven-year-old Immuneering Corp. has raised its first venture round as it gears up to send its inaugural program to the clinic to treat cachexia in cancer patients and extensively expand its pipeline.

Historically, inhalation drug delivery was limited to the treatment and management of respiratory diseases, such as asthma or chronic obstructive pulmonary disease. However, this delivery approach has broadened as an alternative treatment option for a number of systemic diseases,[i] including endocrine and neurological diseases, which could benefit from the frequent pulsatile administration afforded by an

Synaptive Medical Inc. has completed the first round of a new preferred equity investment totaling $25 million led by Guelph-Ontario-based Linamar Corp., which also entered into a manufacturing agreement with Synaptive, and Calgary’s Audible Capital Corp.

As the cost of life-saving insulin soars for people with diabetes, a Cleveland company is developing nanotechnology that could help. The technology, from Diasome, makes insulin more effective in the body so less is needed to regulate blood sugar. Insulin costs for patients with type one diabetes doubled between 2012 and 2016, according to the

Bucks County medical device company Orchestra BioMed said Tuesday it has entered into a $20 million credit agreement with Silicon Valley Bank. This deal provides Orchestra BioMed with an initial amount of up to $10 million it can use for development and general corporate expenditures during the next 12 months. The remaining will be available to the

 A man who lives in Surprise is helping researchers come up with a treatment for a rare disease that he was diagnosed with 20 years ago. Jerry DeVries, now 61, is possibly the oldest living person with Proteus Syndrome.

Rather than picking targets based on conventional approaches, Immunome is letting a patient‘s ability to fight the disease guide target selection and therapy identification.

We are always acutely aware of investors’ appetite to participate in financing deals, and to what degree. There has been a lot of chatter about the “window closing” in 2020, but from what we can see, financing deals for good science and novel ideas are still getting done, and we’re cautiously optimistic that the environment

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world’s priciest medicines. The full scope of Novartis’ (NOVN.S) $500 million plan, revealed to Reuters in an interview with

There is a great need for transformative treatments that increase life expectancy and improve the quality of life of patients and families living with rare inherited diseases. Current therapeutic approaches, including small molecules and enzyme replacement therapies, have limitations and cannot be applied to every disease. ProQR specializes in the development of RNA therapies and

As of Nov. 21, Arrowhead stock is trading at a record high of $49 a share. It has a new slate of drugs that use slightly different molecular technology to silence disease-causing genes and is targeting a range of different diseases. Several of those drugs are now going through clinical trials with promising early results.

Manufacturing today’s cell therapies remains expensive and complex due to the need for viruses or electric shocks to engineer patient cells. Yescarta®, for example, one of the first CAR-T therapies approved for sale, takes 3-4 weeks to reach patients and has a price tag of $373,000.00. With CAR-T, expanding out a patient’s T-cells and transducing them with